118 related articles for article (PubMed ID: 19574781)
21. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger.
Ota T; Yoshida M; Kimura M; Kinoshita K
Int J Gynecol Cancer; 2005; 15(4):657-62. PubMed ID: 16014120
[TBL] [Abstract][Full Text] [Related]
22. Coordinate expression of Cdc25B and ER-alpha is frequent in low-grade endometrioid endometrial carcinoma but uncommon in high-grade endometrioid and nonendometrioid carcinomas.
Wu W; Slomovitz BM; Celestino J; Chung L; Thornton A; Lu KH
Cancer Res; 2003 Oct; 63(19):6195-9. PubMed ID: 14559803
[TBL] [Abstract][Full Text] [Related]
23. Surgical stage, final grade, and survival of women with endometrial carcinoma whose preoperative endometrial biopsy shows well-differentiated tumors.
Eltabbakh GH; Shamonki J; Mount SL
Gynecol Oncol; 2005 Nov; 99(2):309-12. PubMed ID: 16005945
[TBL] [Abstract][Full Text] [Related]
24. Advanced endometrial cancer with serous metastasis in a 17-year-old.
Cohn DE; Resnick KE; Ramirez NC; Morrison CD
Gynecol Oncol; 2006 May; 101(2):356-9. PubMed ID: 16499956
[TBL] [Abstract][Full Text] [Related]
25. Polypoid nodular histiocytic hyperplasia associated with endometrioid adenocarcinoma of the endometrium: report of a case.
Akhter S; Lawrence WD; Quddus MR
Diagn Pathol; 2014 May; 9():93. PubMed ID: 24885845
[TBL] [Abstract][Full Text] [Related]
26. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
27. Role of bcl-2 in endometrioid corpus cancer: an experimental study.
Mariani A; Sebo TJ; Cliby WA; Keeney GL; Riehle DL; Lesnick TG; Podratz KC
Anticancer Res; 2006; 26(2A):823-7. PubMed ID: 16619475
[TBL] [Abstract][Full Text] [Related]
28. Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact.
Ahmed QF; Gattoc L; Al-Wahab Z; Abdulfatah E; Ruterbusch JJ; Cote M; Bandyopadhyay S; Morris RT; Ali-Fehmi R
Am J Surg Pathol; 2015 Feb; 39(2):221-6. PubMed ID: 25517962
[TBL] [Abstract][Full Text] [Related]
29. [Correlations of p-AKT with PTEN, P53, HER-2 expressions in endometrial carcinoma and their relationship with patient survival].
Zhang XM; Liang Y; Dong Y; Zhang Y; Wang Y; Meng YT; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Feb; 44(1):135-41. PubMed ID: 22353917
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
Chapel DB; Yamada SD; Cowan M; Lastra RR
Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
[TBL] [Abstract][Full Text] [Related]
31. [Expression of beta-catenin, Glut-1, PTEN proteins in uterine endometrioid adenocarcinoma and its precursor lesions].
Xiong Y; Xiong YY; Zhou YF
Zhonghua Bing Li Xue Za Zhi; 2009 Sep; 38(9):594-9. PubMed ID: 20079187
[TBL] [Abstract][Full Text] [Related]
32. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
33. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
34. L-type amino acid transporter 1 expression increases in well-differentiated but decreases in poorly differentiated endometrial endometrioid adenocarcinoma and shows an inverse correlation with p53 expression.
Watanabe J; Yokoyama Y; Futagami M; Mizunuma H; Yoshioka H; Washiya K; Hana K; Endou H; Okayasu I
Int J Gynecol Cancer; 2014 May; 24(4):659-63. PubMed ID: 24694899
[TBL] [Abstract][Full Text] [Related]
35. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
36. Dual expression of immunoreactive estrogen receptor β and p53 is a potential predictor of regional lymph node metastasis and postoperative recurrence in endometrial endometrioid carcinoma.
Obata T; Nakamura M; Mizumoto Y; Iizuka T; Ono M; Terakawa J; Daikoku T; Fujiwara H
PLoS One; 2017; 12(11):e0188641. PubMed ID: 29190668
[TBL] [Abstract][Full Text] [Related]
37. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses.
Lax SF; Kurman RJ
Verh Dtsch Ges Pathol; 1997; 81():228-32. PubMed ID: 9474874
[TBL] [Abstract][Full Text] [Related]
38. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract][Full Text] [Related]
39. Does the type of surgery for early-stage endometrial cancer affect the rate of reported lymphovascular space invasion in final pathology specimens?
Momeni M; Kolev V; Cardenas-Goicoechea J; Getrajdman J; Fishman D; Chuang L; Kalir T; Rahaman J; Zakashansky K
Am J Obstet Gynecol; 2013 Jan; 208(1):71.e1-6. PubMed ID: 23099190
[TBL] [Abstract][Full Text] [Related]
40. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
